Mr. Robert von der Porten reports

MEDX HEALTH CORP. ANNOUNCES SECOND QUARTER 2014 FINANCIAL RESULTS

MedX Health Corp. has released its results for the three and six months ended June 30, 2014, which are also available on SEDAR.

"The commercial rollout of our skin cancer screening technology, our SIAscopy product line, continues to build a strong footprint across European pharmacies," said Rob von der Porten, chief executive officer of MedX. "Now installed in more than 100 locations in Norway, we expect distribution and revenue to continue growing as we add new distributors and receive certifications in new jurisdictions, such as Australia."

The company reported a loss of $9,972, or nil per share, for the three months ended June 30, 2014, compared with a loss of $174,807 or nil per share for the three months ended June 30, 2013. The lower loss resulted from a debt settlement gain of $261,363 during the second quarter. Revenues of $220,019 for the second quarter of 2014 were higher than revenue of $190,366 in 2013, due to increased revenue from the company's SIAscopy product line.

For the six-month period, the company reported a loss of $278,704, or nil per share for the six months ended June 30, 2014, compared with a loss of $523,477 or nil per share for the 2013 period. Revenues of $377,791 for the first half of 2014 were higher than revenue of $309,794 in 2013.

"Skin cancer is the most common cancer in the world, and regrettably, someone dies every hour in the U.S. alone from melanoma," added Mr. von der Porten. "The sad part is, it doesn't have to be this way. When detected early, the vast majority of skin cancer is preventable. That is why we are committed to our strategy of having state-of-the-art and proven screening technology conveniently and broadly located in accessible locations, such as in neighbourhood pharmacies."

We seek Safe Harbor.